| Supramaximal doses of botulinum toxin for refractory blepharospasm. | |
| | |
MedLine Citation:
|
PMID: 16828511 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To investigate the response to supramaximal doses of botulinum toxin in patients with refractory blepharospasm. DESIGN: Prospective, nonrandomized, open-label interventional case series. PARTICIPANTS: Eight consecutive patients with blepharospasm requiring injections every 2 months despite receiving 100 U of botulinum toxin per session. INTERVENTION: Increasing the dose of botulinum toxin per session above the conventional maximum. MAIN OUTCOME MEASURES: Duration of treatment effect and patients' subjective response to treatment. RESULTS: Supramaximal dosages were well tolerated. Seven of 8 patients had a prolonged interval between injections relative to that associated with their previous dosing regimen. Four of the patients elected to continue with the new dosage. CONCLUSION: In select patients with essential blepharospasm who are refractory to standard treatment regimens, increasing the dosage of botulinum toxin above 100 U per session may decrease the interval between injections, improve the patient's quality of life, or both. |
| | |
Authors:
|
Richard L Levy; Dalia Berman; Mona Parikh; Neil R Miller |
Publication Detail:
|
Type: Journal Article Date: 2006-07-07 |
Journal Detail:
|
Title: Ophthalmology Volume: 113 ISSN: 1549-4713 ISO Abbreviation: Ophthalmology Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-09-04 Completed Date: 2006-09-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7802443 Medline TA: Ophthalmology Country: United States |
Other Details:
|
Languages: eng Pagination: 1665-8 Citation Subset: IM |
Affiliation:
|
Neuro-ophthalmology Unit, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland 21287, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Blepharospasm / drug therapy* Botulinum Toxin Type A / administration & dosage* Female Humans Injections, Intramuscular Male Maximum Tolerated Dose Middle Aged Neuromuscular Agents / administration & dosage* Prospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Botulinum Toxin Type A; 0/Neuromuscular Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Metastatic retinoblastoma clinical features, treatment, and prognosis.
Next Document: Complement factor H increases risk for atrophic age-related macular degeneration.